Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06960928 · ClinicalTrials.gov registry record · Phase 3

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

A Phase 3 study of Long COVID-19, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 3
Development phase
80
Enrollment target
1
Study location

NCT06960928 is a Phase 3 study of Long COVID-19 that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 80 participants, below the 305-participant average among 10 other Long COVID-19 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06960928, a Phase 3 study of Long COVID-19, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 3
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo. This study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.

Conditions Studied

Long COVID-19

Interventions

  • DRUG Placebo
  • DRUG Low-dose sirolimus

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-04-18
Est. Completion 2026-11-30
Phase Phase 3

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06960928

The ClinicalTrials.gov registry entry for NCT06960928 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 305-participant average among 10 other Long COVID-19 trials with a reported enrollment target (74% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Long COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06960928 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06960928 about?

NCT06960928 is a clinical study titled "Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19". The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 a...

What is the current status of trial NCT06960928?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2025-04-18. Estimated completion is 2026-11-30.

What conditions does trial NCT06960928 study?

This clinical trial studies the following conditions: Long COVID-19.

What interventions are being tested in trial NCT06960928?

The interventions under investigation include: Placebo (DRUG), Low-dose sirolimus (DRUG).

Who is sponsoring clinical trial NCT06960928?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06960928 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID-19

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.